Path of Science: International Electronic Scientific Journal

Antibiotic-induced dysbiosis disrupts the gut microbiota's biochemical symphony, impairing metabolic, immune, and signalling functions essential for health. This multidisciplinary review consolidates molecular, biochemical, and translational insights into biotechnological strategies for microbiota restoration. Topics include engineered probiotics, synthetic microbial consortia, phage-based therapeutics, and metabolic reconstruction of short-chain fatty acid and bile acid pathways. Computational modelling and multi-omics integration are examined as tools for pathway prediction and ecological resilience testing. Clinical and ethical perspectives highlight ongoing trials, biosafety frameworks, and equitable access in low-resource settings. Synthesising findings from systems biology and clinical translation, the review concludes that the next frontier of microbiome therapeutics lies in rationally engineered metabolic restoration—a convergence of biotechnology, computation, and ethics aimed at transforming post-antibiotic medicine into a programmable, functionally resilient ecosystem.

antibiotic-induced dysbiosis; metabolic reconstruction; engineered probiotics; computational modelling; clinical microbiome therapeutics; systems biology

1. Tortora, G. J., Funke, B. R., & Case, C. L. (2023). Microbiology: An introduction (14th ed.). Pearson Education.

2. Prescott, L. M., Klein, D. A., & Harley, J. P. (2008). Microbiology (6th ed). New York: McGraw-Hill

3. Ruan, W., Engevik, M. A., Spinler, J. K., & Versalovic, J. (2020). Healthy human gastrointestinal microbiome: Composition and function after a decade of exploration. Digestive Diseases and Sciences, 65(3), 695–705. doi: 10.1007/s10620-020-06118-4

4. Hollister, E. B., Gao, C., & Versalovic, J. (2014). Compositional and functional features of the gastrointestinal microbiome and their effects on human health. Gastroenterology, 146(6), 1449–1458. doi: 10.1053/j.gastro.2014.01.052

5. Fassarella, M., Blaak, E. E., Penders, J., Nauta, A., Smidt, H., & Zoetendal, E. G. (2020). Gut microbiome stability and resilience: elucidating the response to perturbations to modulate gut health. Gut, 70(3), 595–605. doi: 10.1136/gutjnl-2020-321747

6. Thursby, E., & Juge, N. (2017). Introduction to the human gut microbiota. Biochemical Journal, 474(11), 1823–1836. doi: 10.1042/bcj20160510

7. Aljeradat, B., Kumar, D., Abdulmuizz, S., Kundu, M., Almealawy, Y. F., Batarseh, D. R., Atallah, O., Ennabe, M., Alsarafandi, M., Alan, A., & Weinand, M. (2024). Neuromodulation and the Gut–Brain axis: therapeutic mechanisms and implications for gastrointestinal and neurological disorders. Pathophysiology, 31(2), 244–268. doi: 10.3390/pathophysiology31020019

8. Cusumano, G., Flores, G. A., Venanzoni, R., & Angelini, P. (2025). The impact of antibiotic therapy on intestinal microbiota: dysbiosis, antibiotic resistance, and restoration strategies. Antibiotics, 14(4), 371. doi: 10.3390/antibiotics14040371

9. Ney, L., Wipplinger, M., Grossmann, M., Engert, N., Wegner, V. D., & Mosig, A. S. (2023). Short-chain fatty acids: key regulators of the local and systemic immune response in inflammatory diseases and infections. Open Biology, 13(3), 230014. doi: 10.1098/rsob.230014

10. Rahmati, R., Zarimeidani, F., Boroujeni, M. R. G., Sadighbathi, S., Kashaniasl, Z., Saleh, M., & Alipourfard, I. (2025). CRISPR-Assisted Probiotic and in Situ Engineering of Gut Microbiota: A Prospect for Modification of Metabolic Disorders. Probiotics and Antimicrobial Proteins. doi: 10.1007/s12602-025-10561-y

11. Xavier, K. B., & Bassler, B. L. (2003). LuxS quorum sensing: more than just a numbers game. Current Opinion in Microbiology, 6(2), 191–197. doi: 10.1016/s1369-5274(03)00028-6

12. Paluch, E., Rewak-Soroczyńska, J., Jędrusik, I., Mazurkiewicz, E., & Jermakow, K. (2020). Prevention of biofilm formation by quorum quenching. Applied Microbiology and Biotechnology, 104(5), 1871–1881. doi: 10.1007/s00253-020-10349-w

13. Nath, A., Bhattacharjee, R., Nandi, A., Sinha, A., Kar, S., Manoharan, N., Mitra, S., Mojumdar, A., Panda, P. K., Patro, S., Dutt, A., Ahuja, R., Verma, S. K., & Suar, M. (2022). Phage delivered the CRISPR-Cas system to combat multidrug-resistant pathogens in the gut microbiome. Biomedicine & Pharmacotherapy, 151, 113122. doi: 10.1016/j.biopha.2022.113122

14. Feng, C., Jin, C., Liu, K., & Yang, Z. (2023). Microbiota-derived short-chain fatty acids: Their role and mechanisms in viral infections. Biomedicine & Pharmacotherapy, 160, 114414. doi: 10.1016/j.biopha.2023.114414

15. Shao, T., Hsu, R., Rafizadeh, D. L., Wang, L., Bowlus, C. L., Kumar, N., Mishra, J., Timilsina, S., Ridgway, W. M., Gershwin, M. E., Ansari, A. A., Shuai, Z., & Leung, P. S. (2023). The gut ecosystem and immune tolerance. Journal of Autoimmunity, 141, 103114. doi: 10.1016/j.jaut.2023.103114

16. Zheng, Z., Wu, L., Han, Y., Chen, J., Zhu, S., Yao, Y., Wang, B., & Li, L. (2021). Gut Microbiota-Controlled tryptophan metabolism improves D-GAL/LPS-Induced acute liver failure in C57BL/6 mice. Engineering, 14, 134–146. doi: 10.1016/j.eng.2020.12.013

17. Aust, A., Vidova, V., Coufalikova, K., Smetanova, S., Kozeluhova, K., Micenkova, L., Videnska, P., Smatana, S., Budinska, E., Borek, I., Janku, P., Klanova, J., Spacil, Z., & Thon, V. (2024). Faecal tryptophan metabolite profiling in newborns in relation to microbiota and antibiotic treatment. Applied Microbiology and Biotechnology, 108(1), 504. doi: 10.1007/s00253-024-13339-4

18. Góralczyk-Bińkowska, A., Szmajda-Krygier, D., & Kozłowska, E. (2022). The Microbiota–Gut–Brain axis in Psychiatric disorders. International Journal of Molecular Sciences, 23(19), 11245. doi: 10.3390/ijms231911245

19. Shayista, H., Prasad, M. N. N., Raj, S. N., Prasad, A., Lakshmi, S., Ranjini, H. K., Manju, K., Ravikumara, N., Chouhan, R. S., Khohlova, O. Y., Perianova, O. V., & Baker, S. (2024). Complexity of antibiotic resistance and its impact on gut microbiota dynamics. Engineering Microbiology, 5(1), 100187. doi: 10.1016/j.engmic.2024.100187

20. Khanna, S. (2021). Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day! Journal of Internal Medicine, 290(2), 294–309. doi: 10.1111/joim.13290

21. Shi, Y., Luo, J., Narbad, A., & Chen, Q. (2023). Advances in Lactobacillus restoration for Β-Lactam Antibiotic-Induced Dysbiosis: A systematic review in intestinal Microbiota and Immune Homeostasis. Microorganisms, 11(1), 179. doi: 10.3390/microorganisms11010179

22. Gao, J., Xu, K., Liu, H., Liu, G., Bai, M., Peng, C., Li, T., & Yin, Y. (2018). Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism. Frontiers in Cellular and Infection Microbiology, 8, 13. doi: 10.3389/fcimb.2018.00013

23. Floc’h, N. L., Otten, W., & Merlot, E. (2010). Tryptophan metabolism, from nutrition to potential therapeutic applications. Amino Acids, 41(5), 1195–1205. doi: 10.1007/s00726-010-0752-7

24. Michaudel, C., Danne, C., Agus, A., Magniez, A., Aucouturier, A., Spatz, M., Lefevre, A., Kirchgesner, J., Rolhion, N., Wang, Y., Lavelle, A., Galbert, C., Da Costa, G., Poirier, M., Lapière, A., Planchais, J., Nádvorník, P., Illes, P., Oeuvray, C., Creusot, L., Michel, M., Benech, N., Bourrier, A., Nion-Larmurier, I., Landman, C., Richard, M. L., Emond, P., Seksik, P., Beaugerie, L., Arguello, R. R., Moulin, D., Mani, S., Dvorák, Z., Bermúdez-Humarán, L. G., Langella, P., & Sokol, H. (2022). Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases. Gut, 72(7), 1296–1307. doi: 10.1136/gutjnl-2022-327337

25. Airola, C., Severino, A., Porcari, S., Fusco, W., Mullish, B. H., Gasbarrini, A., Cammarota, G., Ponziani, F. R., & Ianiro, G. (2023). Future modulation of gut microbiota: from eubiotics to FMT, engineered bacteria, and phage therapy. Antibiotics, 12(5), 868. doi: 10.3390/antibiotics12050868

26. OHSU. (2025). OHSU Research Cores and Shared Resources: Transgenic Mouse Models. Retrieved from https://www.ohsu.edu/sites/default/files/2025-03/SPS%20TGMM%2020250331.pdf

27. Raza, A., Fatima, P., Yasmeen, B., Rana, Z. A., & Ellakwa, D. E. (2024). From resistance to remedy: the role of clustered regularly interspaced short palindromic repeats system in combating antimicrobial resistance—a review. Naunyn-Schmiedeberg S Archives of Pharmacology, 398(3), 2259–2273. doi: 10.1007/s00210-024-03509-6

28. Rocha, E. P. C., Bikard, D., Rocha, E. P. C., & Bikard, D. (2022). Microbial defences against mobile genetic elements and viruses: Who defends whom from what? PLoS Biology, 20(1), e3001514. doi: 10.1371/journal.pbio.3001514

29. Corte, L. E., Mahmoud, L. M., Moraes, T. S., Mou, Z., Grosser, J. W., & Dutt, M. (2019). Development of improved fruit, vegetable, and ornamental crops using the CRISPR/CAS9 genome editing technique. Plants, 8(12), 601. doi: 10.3390/plants8120601

30. Bai, X., Huang, Z., Duraj-Thatte, A. M., Ebert, M. P., Zhang, F., Burgermeister, E., Liu, X., Scott, B. M., Li, G., & Zuo, T. (2023). Engineering the gut microbiome. Nature Reviews Bioengineering, 1(9), 665–679. doi: 10.1038/s44222-023-00072-2

31. Fan, Y., & Pedersen, O. (2020). Gut microbiota in human metabolic health and disease. Nature Reviews Microbiology, 19(1), 55–71. doi: 10.1038/s41579-020-0433-9

32. Singh, V., Lee, G., Son, H., Koh, H., Kim, E. S., Unno, T., & Shin, J. (2023). Butyrate producers, "The Sentinel of Gut": Their intestinal significance with and beyond butyrate, and prospective use as microbial therapeutics. Frontiers in Microbiology, 13, 1103836. doi: 10.3389/fmicb.2022.1103836

33. Sabahat, S. E., Saqib, M., Talib, M., Shaikh, T. G., Khan, T., & Kailash, S. J. (2024). Bile acid modulation by gut microbiota: a bridge to understanding cognitive health. Annals of Medicine and Surgery, 86(9), 5410–5415. doi: 10.1097/ms9.0000000000002433

34. Kim, K., Kang, M., & Cho, B. (2023). Systems and synthetic biology-driven engineering of live bacterial therapeutics. Frontiers in Bioengineering and Biotechnology, 11, 1267378. doi: 10.3389/fbioe.2023.1267378

35. Nakamura, A., & Matsumoto, M. (2025). Role of polyamines in intestinal mucosal barrier function. Seminars in Immunopathology, 47(1), 9. doi: 10.1007/s00281-024-01035-4

36. Mirzaei, S., & Tefagh, M. (2024). GEM-based computational modelling for exploring metabolic interactions in a microbial community. PLoS Computational Biology, 20(6), 1012233. doi: 10.1371/journal.pcbi.1012233

37. Braat, H., Rottiers, P., Hommes, D. W., Huyghebaert, N., Remaut, E., Remon, J., Van Deventer, S. J., Neirynck, S., Peppelenbosch, M. P., & Steidler, L. (2006). A Phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clinical Gastroenterology and Hepatology, 4(6), 754–759. doi: 10.1016/j.cgh.2006.03.028

38. Noguès, E. B., Kropp, C., Bétemps, L., De Sousa, C., Chain, F., Auger, S., Azevedo, V., Langella, P., & Chatel, J. (2022). Lactococcus lactis engineered to deliver hCAP18 cDNA alleviates DNBS-induced colitis in C57BL/6 mice by promoting IL17A and IL10 cytokine expression. Scientific Reports, 12(1), 15641. doi: 10.1038/s41598-022-19455-3

39. Zikou, E., Koliaki, C., & Makrilakis, K. (2024). The role of faecal microbiota transplantation (FMT) in the management of metabolic diseases in humans: a narrative review. Biomedicines, 12(8), 1871. doi: 10.3390/biomedicines12081871

40. Wandro, S., Ghatbale, P., Attai, H., Hendrickson, C., Samillano, C., Suh, J., Dunham, S. J. B., Pride, D. T., & Whiteson, K. (2022). Phage cocktails constrain Enterococcus growth. mSystems, 7(4), e0001922. doi: 10.1128/msystems.00019-22

41. Kim, K., Choe, D., Song, Y., Kang, M., Lee, S., Lee, D., & Cho, B. (2021). Engineering Bacteroides thetaiotaomicron to produce non-native butyrate via genome-scale metabolic model-guided design. Metabolic Engineering, 68, 174–186. doi: 10.1016/j.ymben.2021.10.005

42. Arratia-Quijada, J., Nuño, K., Ruíz-Santoyo, V., & Andrade-Espinoza, B. A. (2024). Nano-encapsulation of probiotics: Need and critical considerations to design new non-dairy probiotic products. Journal of Functional Foods, 116, 106192. doi: 10.1016/j.jff.2024.106192

43. Pan, T., Cha, J., Wang, H., Zhang, J., Xiao, J., Shen, J., Zhou, M., Li, Y., Ma, J., Zhao, K., Zhang, Y., Xiao, P., & Gao, H. (2025). The CRISPR/Cas9-Mediated Knockout of VgrG2 in Wild Pathogenic E. coli to Alleviate the Effects on Cell Damage and Autophagy. Veterinary Sciences, 12(3), 249. doi: 10.3390/vetsci12030249

44. Khanna, S. (2024). Microbiota restoration for recurrent Clostridioides difficile infection. Panminerva Medica, 66(4), 417–426. doi: 10.23736/s0031-0808.24.05111-5

45. De Lorenzo, V., & Danchin, A. (2008). Synthetic biology: discovering new worlds and new words. EMBO Reports, 9(9), 822–827. doi: 10.1038/embor.2008.159

46. Federici, S., Nobs, S. P., & Elinav, E. (2020). Phages and their potential to modulate the microbiome and immunity. Cellular and Molecular Immunology, 18(4), 889–904. doi: 10.1038/s41423-020-00532-4

47. Ramírez, A., Bermúdez-Luque, A., Román-Camacho, J. J., Martín-García, F. J., Moreno-García, J., Güngörmüşler, M., & Ruiz-Castilla, F. J. (2025). Exploring the future of probiotics with innovations in delivery systems and market insights. Food Bioscience, 71, 107029. doi: 10.1016/j.fbio.2025.107029

48. Wang, Z., Wang, S., He, Q., Yang, X., Zhao, B., Zhang, H., & Deng, Y. (2025). Ecological design of high-performance synthetic microbial communities: from theoretical foundations to functional optimisation. ISME Communications, 5(1), ycaf133. doi: 10.1093/ismeco/ycaf133